Preliminary studies have shown that targeting overexpressed molecules like mucin 16 (MUC16), annexin 2 (ANXA2), and also HER2 can sustain high tumor cells toxicity, and so dwindle tumor burden [134]. The gene discussed is MUC16; the disease is neoplasm.